Financings

Emerald Health Therapeutics Inc.entered a binding term sheet with a single Canadian institutional accredited investor for the purchase of 2,500 secured convertible debenture units at $10,000 each for gross proceeds of $25 million.

Essa Pharma Inc. closed a public offering in Canada and a concurrent private placement of equity securities in the U.S. for aggregate gross proceeds of $36 million.

Hifibio Therapeuticscompleted a $67 million series C financing round.

Deals

Amgen Inc. is picking up Celgene Corp.'s oral phosphodiesterase 4 (PDE4) inhibitor Otezla (apremilast) for $13.4 billion, in a move that strengthens its hand in inflammatory disease, while paving the way for Bristol-Myers Squibb Co. to complete its $74 billion cash-and-shares acquisition of Celgene.

Celgene Corp. entered a partnership with Immatics Biotechnologies GmbH involving up to three adoptive cell therapies expressing proprietary T-cell receptors directed against undisclosed Immatics-discovered intracellular peptide cancer targets.

Crozet Biopharma LLCentered a $10.8 million partnering agreement with Public Health Vaccines LLC to advance the development and manufacture of a rVSV-Nipah vaccine against the Nipah virus, listed as a priority pathogen by the World Health Organization.

Darwinhealth signed a multi-year scientific research collaboration with Celgene Corp. to use quantitative systems biology-based algorithms to support clinical development efforts.

Hotspot Therapeutics Inc.acquired Macroceutics Inc., a provider of DNA-encoded library screening technologies. The deal will enhance Hotspot's platform, which is designed to predict, drug and differentiate unique regulatory hotspots on proteins.

The Ivy Brain Tumor Center at the Barrow Neurological Institute and Salarius Pharmaceuticals Inc.have established a collaborative partnership to test the company's therapeutic candidate, seclidemstat, for the treatment of glioblastoma.

Zogenix Inc.entered into a definitive agreement to acquire Modis Therapeutics Inc. that is developing therapies for rare genetic diseases.

... And more

Abbvie Inc.'s multibillion-dollar acquisition of Stemcentrx Inc. came up short after its lead product rovalpituzumab tesirine (Rova-T) failed to help people with advanced small-cell lung cancer live any longer than a placebo.

Edigene Corp.said its corporate name was changed to Modalis Therapeutics Corp. to better reflect its emerging gene modulation technology.

Efforts to lower drug prices have led to a steady increase in FDA approvals of abbreviated new drug applications, including first-time generics. With 73 approvals currently, and a projected 109 by the end of the year, the number of first-time generic approvals has risen 49% since 2016.

Hemispherx Biopharma Inc. is changing its name to Aim Immunotech Inc. and the company's new ticker symbol will be AIM.

Johnson & Johnson's "misleading marketing and promotion" of opioids created a nuisance that compromised the health and safety of thousands of Oklahomans, an Oklahoma judge ruled. In a first-of-its-kind case, Judge Thad Balkman ordered J&J to pay more than $572 million to immediately abate the nuisance he said the company and its subsidiary, Janssen Pharmaceuticals Inc., caused.

Proteona Pte. Ltd.has agreed to participate in AI Singapore's 100 Experiments program, which aims to solve challenges in single cell data analysis using artificial intelligence tools

The Malaria Cell Atlas of gene expression in the malaria parasite Plasmodium shows exactly which genes are active at each stage of the complex life cycle of the single cell organism in the mosquito vector and the human host. It also provides new insights into the roles of the 40% of Plasmodium genes whose function is unknown and shows clusters of genes are expressed across the life span, pointing to a number of new therapeutic and diagnostic targets.

The next wave of drug discovery is being enabled by powerful computers dining on complex algorithms to uncover potential new scientific approaches for the development of innovative therapeutics. While it is still early days, over the past two years companies in this space have already attracted well in excess of $1 billion in venture capital.

No Comments